NRx notes real-world study showing IV ketamine beats nasal esketamine on depression remission, response rates

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00
  • NRx Pharmaceuticals flagged results already presented in a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology meeting.
  • Real-world electronic health record analysis compared IV ketamine with intranasal esketamine in adults with treatment-resistant depression across community psychiatry clinics.
  • IV ketamine showed higher rates of symptom improvement, response, and remission than intranasal esketamine in routine clinical care.
  • Findings were limited by non-random treatment assignment, raising the risk that patient differences influenced outcomes.
  • NRx highlighted the data as supportive of its IV ketamine program as it pursues a regulatory path that incorporates real-world evidence.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050850PRIMZONEFULLFEED9732478) on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.